Omada Grew 43% in Q2, Yet Its Guidance Leaves Only 19% for H2

The headline numbers:

Lining up the last four quarters tells you more than any single one:

There's a clear pattern here: the first quarter is always the trough. Every January a wave of new members comes on board as employers' benefit years reset, and Omada has to ship them connected glucose meters, blood-pressure cuffs and scales first. Hardware is a bigger slice of revenue and carries thin margins, so gross margin slid from 71% in the prior Q4 to 62%, and the company dipped back into a loss. By Q2 those new members are absorbed, the services mix recovers, and margins bounce back. So the fair comparison for Q2's 73% isn't Q1's 62% but last Q4's 71% — a genuine structural improvement of roughly two percentage points. On top of that, management said on the call that AI-assisted coaching has cut service cost per member by about 10% (Q2 call, compiled by Stock Taper).

The problem is the guidance math. First-half revenue of $78 million plus $87.8 million comes to $165.8 million:

Last year's two second-half quarters totaled $144 million, so the midpoint implies only 19% growth in the back half. And if Q3 and Q4 come in equal, Q3 would be roughly 2.5% below Q2's $87.8 million. Adjusted EBITDA tells the same story: about $12 million is already banked in the first half, so full-year guidance of $21–27 million leaves just $4.5–7.5 million per quarter in the second half — well short of Q2's $11 million. Management itself called it an "extraordinary second quarter performance," yet the press release doesn't break out how much of Q2 revenue came from one-time settlements or retroactive recognition under performance-based (pay-for-outcomes) contracts. We could not find that figure in public disclosures.

Guidance that treated Q2 as the new normal would have projected a stronger second half; guidance that treats Q2 as a fluke looks exactly like this. The number to watch in the next report is whether Q3 revenue lands above or below $85.6 million. Holding above $87.8 million would mean the Q2 jump is sustainable and leave room for another guidance raise. Falling below $84.1 million would suggest Q2 really was inflated by one-off items.

The demand evidence, at least, is solid. Member growth of 45% is driving the top line, while revenue per member rose only 2% — growth is almost entirely about volume. HCSC (the largest non-profit Blue Cross Blue Shield insurer in the US) is extending Omada's diabetes-prevention and hypertension programs to its fully insured business in three more states, adding 1.5 million covered lives. That goes live in 2027, and management expects it to start contributing revenue in the first half of 2027. In July Omada launched its first cholesterol-management program and signed its first customer for its GLP-1 prescribing program (company release 2026-08-06; Q2 call). In management's words: "At the midpoint, our raised full year outlook represents approximately 30% year over year revenue growth and a fourfold increase in adjusted EBITDA."

Omada runs an asset-light software-plus-services model, and capital spending is a rounding error. The real question for this section is how good the profits are.

With $222 million in cash, zero debt and adjusted EBITDA turning positive for the full year, Omada faces no near-term funding pressure; the idea that it needs to raise money within a year doesn't hold up. What deserves a closer look is the gap between GAAP and adjusted figures. Q2 adjusted EBITDA was $11 million against GAAP net income of $5.3 million; the difference is mostly SBC, depreciation and amortization, minus interest income. At today's interest rates, $222 million in cash throws off meaningful interest each year — so part of GAAP net income comes from the balance sheet rather than the business. Operating cash flow of $3.5 million versus $11 million in adjusted EBITDA means a cash conversion rate of just over 30%. The reason: performance-based contracts come with long receivables cycles, and large employers and health plans often settle quarterly or even annually.

SBC at around 5% of revenue is restrained for a digital-health company barely a year past its IPO. Still, employee options and RSUs granted since the June 2025 IPO will keep diluting shareholders, and the share count needs to be checked against the Q3 10-Q. We could not find a precise dilution figure in this quarter's release, so we won't estimate one.

Omada's supply side is simpler than it looks. On the hardware end are connected glucose meters, blood-pressure monitors and scales. Hardware revenue was $7.1 million in Q2 and $8.5 million in Q1 (10-Q). The company doesn't name its contract manufacturers and we couldn't identify them, but these are mature, commodity devices that are unlikely to become a bottleneck. The real bottleneck is people. Every member is backed by health coaches, registered dietitians and clinical staff; if the coaching team grows in a straight line with membership, it eats the margin. Management credits AI assistance with the 10% cut in service cost per member — the key support behind Q2's 73% gross margin, and the piece most likely to be proven or disproven in the second half.

On the paying side are three kinds of customers: employers, health plans and pharmacy benefit managers (PBMs). In its Q1 release the company said it now works with all three of the largest US PBMs (company release 2026-05-07). That channel lets Omada bundle itself into PBM prescription-benefit packages sold to thousands of employers, at the cost of PBM price pressure and a revenue share. We could not find single-customer revenue concentration in this quarter's release.

The biggest source of inflation in these contracts is the "covered lives" figure. HCSC's 1.5 million new covered lives are like a shopping mall announcing how many people live nearby — the people who actually walk in and buy are only those diagnosed with prediabetes or hypertension who actively sign up. Fully insured business does skip the employer-by-employer sales cycle, since members can enroll directly at the benefit level, but enrollment rates won't be visible until the program launches in 2027. The 1.5 million figure absolutely cannot be converted straight into members.

The most fragile link is employers' stance on paying for GLP-1 weight-loss drugs. Omada's GLP-1 Care Track wins members from among employees whose employers cover those drugs, and management flagged uncertainty around "employer decisions on GLP-1 coverage" on the call (Q2 call). If large employers tighten GLP-1 coverage during year-end open enrollment, this fastest-growing product line takes the first hit.

The most comparable group is Omada's fellow health-information-services companies that just reported 2026Q2. Revenue growth, ranked (each company's 2026Q2 report):

Omada sits at the tail of the top tier, but it's the only company in the group whose growth rests almost entirely on member count. Its closest twin is Hinge Health (HNGE): both sell virtual care through employers, and both listed in mid-2025. Hinge focuses on musculoskeletal conditions — exactly the turf where Omada's physical-therapy program competes. Hinge grew 53% this quarter and disclosed $861.8 million in bookings. Omada discloses no comparable bookings or backlog figure, which makes it much harder for outsiders to read next year's revenue floor in advance the way they can with Hinge. Directionally, almost every company in this group raised guidance around August, with HQY, CARL and WAY raising most aggressively. That points to industry-wide demand from employer benefits: Omada is riding the sector tide (beta) plus its own product expansion.

As for how the market priced these reports on earnings day, we couldn't find usable peer reaction data this quarter, so we won't force a comparison.

The price-to-earnings ratio is essentially useless for Omada. The live P/E is about 85.5x, but the denominator is a thin profit that just flipped from negative to positive — a single quarter's swing could double or halve it. The better tools are EV/Sales alongside EV/adjusted EBITDA, with the "Rule of 40" as a check on the balance between growth and profitability. (Enterprise value, or EV, is market value minus net cash; the Rule of 40 says a healthy software-style company's growth rate plus profit margin should add up to at least 40.)

What does 3.2x EV/Sales mean? For a healthcare SaaS-style business with gross margins above 70% and revenue growing around 30%, it isn't expensive. The market clearly isn't pricing off annualized Q2 — it's pricing off the guidance midpoint, or even a discount to it. Put differently, today's price already bakes in the pessimistic "second-half growth drops to 19%" scenario. Investors are paying only for the 2026 guidance itself, not for HCSC's 2027 ramp or the margin expansion from AI cost savings. The 45x EBITDA multiple looks rich, but its denominator is in a phase of quadrupling in a single year; if margins rise another 3–4 percentage points in 2027, that multiple naturally falls below 30x.

Omada sells a service, so its "cycle" is the employer health-benefits buying cycle plus the GLP-1 drug wave. Three readings help locate it:

Digital chronic-disease management is in the middle of its upswing. Employer cost-control needs and the support services that GLP-1 drugs require are still expanding — the near-unanimous guidance raises across peers are evidence of that. But member growth has slipped from around 50% to the mid-40s and pricing is flat, the classic look of a mid-cycle phase shading into late-cycle.

Two leading signals are worth tracking. First, if revenue per member turns negative year over year, PBM and large-customer price pressure is starting to outweigh product expansion; that usually leads a gross-margin decline by one or two quarters. Second, watch large employers' GLP-1 coverage decisions during year-end open enrollment. If big employers cancel or tighten GLP-1 coverage en masse, new-member additions in Q1 2027 will be the first thing to stall.

This section is a week-by-week signal for timing entries and exits over the next few weeks. Readers holding for a year or more can skip it.

One gap up front: there's currently no usable sector money-flow reading for the digital chronic-care niche, and Omada itself hasn't shown any notable unusual money-flow signal over the past month. So we can only infer its environment from the broad market and the healthcare sector.

As of 2026-10-06:

In plain trader language: money is crowding into large-cap tech and semiconductor equipment, while small caps and credit-risk assets are being sold down — and Omada, a $1.3 billion small-cap growth stock that only just turned profitable, sits squarely on the side being drained. Some money is flowing back into healthcare, but it's going to innovation themes with a technology story — AI drug discovery, liquid biopsy, genomics. Digital health services aren't part of this rotation, and Omada's corner doesn't belong to any rotation that's currently forming. The stock has fallen about 14.5% over the past 30 days and now sits below its 50-day moving average but above its 200-day. Without sector money stepping in, the pullback looks more like a passive casualty of the broad small-cap bleed: the stock didn't move ahead of the money, and the money hasn't come back yet. A 5.28% 10-year yield also weighs on the valuations of growth stocks, a persistent headwind for a company whose value depends on profits years out.

Long term (quarters to years): worth following. On fundamentals, Omada has shown with 45% member growth, a 73% gross margin and freshly positive GAAP profit that digital chronic-disease management can scale profitably, and $222 million in cash with no debt means it needs no outside funding. On valuation, 3.2x EV/Sales pays only for the 2026 guidance, not for HCSC's 2027 ramp or AI-driven cost savings. The costs you have to accept are just as clear: guidance already pushes second-half growth down to about 19%; Q3 may well show flat or slightly lower revenue versus Q2; GAAP profit is thin enough that a single quarter could flip it back to a loss; and the January 2027 CEO handover and employers' year-end GLP-1 coverage decisions are variables nobody can rule out in advance. Tie the position to checkpoints: if Q3 revenue holds above the quarterly average implied by the guidance midpoint and gross margin stays around 70%, treat that as evidence Q2 can repeat and add to the position; if not, accept that Q2 had one-off elements and scale back to a watch-only position.

Short term (days to weeks): don't chase — wait for two things. Money flows show small-cap stocks being systematically sold, and the money returning to healthcare is bypassing digital health services, so this stock lacks sector-level buying support. On price, it has just broken below its 50-day moving average while holding above its 200-day, leaving it stuck in a tug-of-war between the medium-term trend and short-term weakness. Until small-cap outflows stop, or the stock reclaims its short-term average, buying means fighting a style headwind. With the Q3 report only a month away in early November, there's no harm in waiting to see whether that report confirms Q2 can be sustained before deciding on timing.

The second half of this note turns these two calls into concrete conditions and price levels.